Related Experiment Video
Updated: Oct 15, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Betulinic Acid Improves Cardiac-Renal Dysfunction Caused by Hypertrophy through Calcineurin-NFATc3 Signaling
Mi-Hyeon Hong1,2, Se-Won Na1,2, Youn-Jae Jang1,2
1Hanbang Cardio-Renal Research Center, Wonkwang University, Iksan 54538, Korea.
Insights
Betulinic acid (BA) effectively treats cardiac hypertrophy and renal dysfunction in rats. This natural compound improved heart function and reduced cardiac biomarkers, offering potential as a functional material.
Area of Science:
- Cardiovascular Pharmacology
- Natural Product Chemistry
- Renal Physiology
Background:
- Cardiac hypertrophy is a major cause of heart failure, mortality, and morbidity worldwide.
- Existing treatments for cardiac hypertrophy and associated renal dysfunction are limited.
- Betulinic acid (BA), a natural compound, exhibits various physiological effects, but its role in cardiac hypertrophy is unexplored.
Purpose of the Study:
- To investigate the effects of Betulinic acid (BA) on isoprenaline (ISO)-induced cardiac hypertrophy in Sprague Dawley rats.
- To evaluate BA's impact on cardiac function, cardiac hypertrophy biomarkers, and related signaling pathways.
- To assess BA's efficacy in mitigating renal dysfunction secondary to cardiac hypertrophy.
Main Methods:
- Cardiac hypertrophy was induced in Sprague Dawley rats using daily intraperitoneal injections of isoprenaline (ISO) for 28 days.
- Betulinic acid (BA) (10 or 30 mg/kg/day) or propranolol (positive control) was administered orally from day 14.
- Cardiac and left ventricular weights, echocardiography, cardiac hypertrophy biomarkers (β-MHC, ANP, BNP, LDH, CK-MB), renal function indicators (creatinine clearance, BUN), and calcineurin/NFATc3 signaling were analyzed.
Main Results:
- BA treatment significantly reduced cardiac and left ventricular weights in ISO-induced hypertrophied hearts.
- Echocardiography confirmed BA's improvement of cardiac function impaired by ISO.
- BA significantly decreased elevated cardiac hypertrophy biomarkers and restored renal function indicators (creatinine clearance, BUN) aggravated by ISO, by inhibiting calcineurin/NFATc3 signaling.
Conclusions:
- Betulinic acid demonstrates significant efficacy in ameliorating cardiac hypertrophy and associated renal dysfunction.
- BA improves cardiac function and reduces hypertrophy markers by modulating the calcineurin/NFATc3 signaling pathway.
- These findings suggest BA holds potential as a functional material for managing cardiac and renal dysfunction.
Abstract:
Cardiac hypertrophy can lead to congestive heart failure and is a leading cause of morbidity and mortality worldwide. In recent years, it has been essential to find the treatment and prevention of cardiac hypertrophy. Betulinic acid (BA), the main active ingredient in many natural products, is known to have various physiological effects. However, as the potential effect of BA on cardiac hypertrophy and consequent renal dysfunction is unknown, we investigated the effect of BA on isoprenaline (ISO)-induced cardiac hypertrophy and related signaling. ISO was known to induce left ventricular hypertrophy by stimulating the β2-adrenergic receptor (β2AR). ISO was injected into Sprague Dawley rats (SD rats) by intraperitoneal injection once a day for 28 days to induce cardiac hypertrophy. From the 14th day onwards, the BA (10 or 30 mg/kg/day) and propranolol (10 mg/kg/day) were administered orally. The study was conducted in a total of 5 groups, as follows: C, control; Is, ISO (10 mg/kg/day); Pr, positive-control, ISO + propranolol (10 mg/kg/day); Bl, ISO + BA (10 mg/kg/day); Bh, ISO + BA (30 mg/kg/day). As a result, the total cardiac tissue and left ventricular tissue weights of the ISO group increased compared to the control group and were significantly reduced by BA treatment. In addition, as a result of echocardiography, the effect of BA on improving cardiac function, deteriorated by ISO, was confirmed. Cardiac hypertrophy biomarkers such as β-MHC, ANP, BNP, LDH, and CK-MB, which were increased by ISO, were significantly decreased by BA treatment. Also, the cardiac function improvement effect of BA was confirmed to improve cardiac function by inhibiting calcineurin/NFATc3 signaling. Renal dysfunction is a typical complication caused by cardiac hypertrophy. Therefore, the study of renal function indicators, creatinine clearance (Ccr) and osmolality (BUN) was aggravated by ISO treatment but was significantly restored by BA treatment. Therefore, it is thought that BA in cardiac hypertrophy can be used as valuable data to develop as a functional material effective in improving cardiac-renal dysfunction.
More Related Videos
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Heart Failure Drugs: β-Blockers
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Action of β1 Blockers
Heart Failure II: Pathophysiology

